hydrocortisone succinate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| corticosteroids, except prednisolone derivatives | 4456 | 125-04-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 27, 1955 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infusion related reaction | 399.95 | 14.26 | 264 | 10614 | 100944 | 46574240 |
| Flushing | 95.35 | 14.26 | 95 | 10783 | 64519 | 46610665 |
| Urticaria | 48.08 | 14.26 | 93 | 10785 | 117799 | 46557385 |
| Febrile neutropenia | 45.31 | 14.26 | 80 | 10798 | 94547 | 46580637 |
| Anaphylactic shock | 41.88 | 14.26 | 36 | 10842 | 20238 | 46654946 |
| Disseminated intravascular coagulation | 35.75 | 14.26 | 32 | 10846 | 18973 | 46656211 |
| Pyrexia | 35.62 | 14.26 | 168 | 10710 | 348634 | 46326550 |
| Toxicity to various agents | 32.99 | 14.26 | 5 | 10873 | 211761 | 46463423 |
| Chest discomfort | 28.34 | 14.26 | 64 | 10814 | 90205 | 46584979 |
| Blood pressure fluctuation | 27.99 | 14.26 | 35 | 10843 | 30413 | 46644771 |
| Colitis ulcerative | 27.84 | 14.26 | 27 | 10851 | 17705 | 46657479 |
| Septic shock | 27.75 | 14.26 | 49 | 10829 | 57844 | 46617340 |
| Blood pressure decreased | 26.91 | 14.26 | 48 | 10830 | 57111 | 46618073 |
| Pruritus | 26.36 | 14.26 | 119 | 10759 | 242233 | 46432951 |
| Product use issue | 25.26 | 14.26 | 63 | 10815 | 94581 | 46580603 |
| Drug ineffective | 25.21 | 14.26 | 78 | 10800 | 677760 | 45997424 |
| Erythema | 24.44 | 14.26 | 81 | 10797 | 142739 | 46532445 |
| Abdominal pain | 24.30 | 14.26 | 112 | 10766 | 229919 | 46445265 |
| Shock | 23.16 | 14.26 | 27 | 10851 | 21818 | 46653366 |
| Dyspnoea | 22.38 | 14.26 | 200 | 10678 | 515348 | 46159836 |
| Genital rash | 22.01 | 14.26 | 7 | 10871 | 477 | 46674707 |
| Cytomegalovirus infection | 21.92 | 14.26 | 24 | 10854 | 18120 | 46657064 |
| Cytomegalovirus viraemia | 20.84 | 14.26 | 13 | 10865 | 4465 | 46670719 |
| Endometritis decidual | 20.26 | 14.26 | 4 | 10874 | 36 | 46675148 |
| Oxygen saturation decreased | 19.47 | 14.26 | 47 | 10831 | 69117 | 46606067 |
| Aspartate aminotransferase increased | 18.54 | 14.26 | 50 | 10828 | 78650 | 46596534 |
| Tracheal inflammation | 18.51 | 14.26 | 4 | 10874 | 58 | 46675126 |
| Platelet count decreased | 18.24 | 14.26 | 58 | 10820 | 99966 | 46575218 |
| Feeling hot | 18.04 | 14.26 | 32 | 10846 | 37896 | 46637288 |
| Apocrine miliaria | 17.94 | 14.26 | 3 | 10875 | 9 | 46675175 |
| Drug interaction | 17.58 | 14.26 | 13 | 10865 | 203081 | 46472103 |
| Neutrophil count decreased | 17.35 | 14.26 | 34 | 10844 | 43392 | 46631792 |
| Intestinal resection | 17.19 | 14.26 | 9 | 10869 | 2221 | 46672963 |
| Hypofibrinogenaemia | 16.60 | 14.26 | 7 | 10871 | 1063 | 46674121 |
| Heart rate increased | 16.11 | 14.26 | 46 | 10832 | 74745 | 46600439 |
| Bronchospasm | 15.96 | 14.26 | 19 | 10859 | 15688 | 46659496 |
| Adrenocortical insufficiency acute | 15.26 | 14.26 | 7 | 10871 | 1299 | 46673885 |
| Adrenal insufficiency | 15.23 | 14.26 | 17 | 10861 | 13107 | 46662077 |
| Throat tightness | 14.78 | 14.26 | 21 | 10857 | 20618 | 46654566 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infusion related reaction | 325.84 | 14.90 | 182 | 8714 | 40382 | 29903200 |
| Pyrexia | 63.15 | 14.90 | 211 | 8685 | 294278 | 29649304 |
| Disseminated intravascular coagulation | 54.03 | 14.90 | 48 | 8848 | 22123 | 29921459 |
| Flushing | 53.09 | 14.90 | 54 | 8842 | 29438 | 29914144 |
| Febrile neutropenia | 51.58 | 14.90 | 104 | 8792 | 106589 | 29836993 |
| Platelet count decreased | 41.56 | 14.90 | 95 | 8801 | 106034 | 29837548 |
| Toxicity to various agents | 33.72 | 14.90 | 6 | 8890 | 177177 | 29766405 |
| Urticaria | 32.23 | 14.90 | 58 | 8838 | 54548 | 29889034 |
| Chills | 31.95 | 14.90 | 68 | 8828 | 72270 | 29871312 |
| Anaphylactic shock | 29.60 | 14.90 | 28 | 8868 | 13965 | 29929617 |
| Neutrophil count decreased | 28.85 | 14.90 | 48 | 8848 | 42406 | 29901176 |
| Septic shock | 28.33 | 14.90 | 60 | 8836 | 63547 | 29880035 |
| Chest discomfort | 27.72 | 14.90 | 49 | 8847 | 45431 | 29898151 |
| Acute graft versus host disease in skin | 27.53 | 14.90 | 17 | 8879 | 4499 | 29939083 |
| Anaphylactic reaction | 26.61 | 14.90 | 37 | 8859 | 27945 | 29915637 |
| Blood pressure decreased | 26.50 | 14.90 | 49 | 8847 | 47026 | 29896556 |
| Product use issue | 26.03 | 14.90 | 48 | 8848 | 45968 | 29897614 |
| Cytomegalovirus infection | 25.09 | 14.90 | 33 | 8863 | 23641 | 29919941 |
| Therapeutic product effect prolonged | 23.97 | 14.90 | 7 | 8889 | 279 | 29943303 |
| Oxygen saturation decreased | 22.94 | 14.90 | 44 | 8852 | 43396 | 29900186 |
| Antithrombin III decreased | 21.76 | 14.90 | 7 | 8889 | 387 | 29943195 |
| White blood cell count decreased | 21.35 | 14.90 | 64 | 8832 | 83883 | 29859699 |
| Posthaemorrhagic hydrocephalus | 20.76 | 14.90 | 5 | 8891 | 93 | 29943489 |
| Pallor | 20.26 | 14.90 | 28 | 8868 | 21021 | 29922561 |
| Epstein-Barr virus associated lymphoproliferative disorder | 20.22 | 14.90 | 10 | 8886 | 1718 | 29941864 |
| Drug interaction | 19.92 | 14.90 | 18 | 8878 | 199550 | 29744032 |
| Cytomegalovirus viraemia | 19.36 | 14.90 | 15 | 8881 | 5714 | 29937868 |
| Off label use | 19.14 | 14.90 | 133 | 8763 | 249157 | 29694425 |
| Chronic graft versus host disease | 18.96 | 14.90 | 13 | 8883 | 4106 | 29939476 |
| Pneumonia | 18.34 | 14.90 | 165 | 8731 | 334141 | 29609441 |
| Hepatic function abnormal | 18.01 | 14.90 | 39 | 8857 | 41906 | 29901676 |
| Sepsis | 16.93 | 14.90 | 87 | 8809 | 146308 | 29797274 |
| Traumatic shock | 16.35 | 14.90 | 3 | 8893 | 13 | 29943569 |
| Human herpesvirus 6 infection | 16.24 | 14.90 | 9 | 8887 | 1949 | 29941633 |
| Insulin-like growth factor decreased | 15.78 | 14.90 | 5 | 8891 | 263 | 29943319 |
| Phaeochromocytoma crisis | 15.26 | 14.90 | 3 | 8893 | 20 | 29943562 |
| Erythema | 15.14 | 14.90 | 54 | 8842 | 77397 | 29866185 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000893 | Anti-Inflammatory Agents |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Disorder of musculoskeletal system | indication | 928000 | DOID:17 |
| Cerebral edema | indication | 2032001 | |
| Berylliosis | indication | 8247009 | DOID:10322 |
| Psoriasis | indication | 9014002 | DOID:8893 |
| Ankylosing spondylitis | indication | 9631008 | DOID:7147 |
| Rheumatic heart disease | indication | 23685000 | |
| Atopic dermatitis | indication | 24079001 | DOID:3310 |
| Inflammatory bowel disease | indication | 24526004 | DOID:0050589 |
| Multiple sclerosis | indication | 24700007 | DOID:2377 |
| Severe adrenal insufficiency | indication | 24867002 | |
| Sarcoidosis | indication | 31541009 | DOID:11335 |
| Idiopathic thrombocytopenic purpura | indication | 32273002 | DOID:8924 |
| Psoriasis with arthropathy | indication | 33339001 | |
| Crohn's disease | indication | 34000006 | |
| Tendinitis | indication | 34840004 | DOID:971 |
| Erythema multiforme | indication | 36715001 | |
| Contact dermatitis | indication | 40275004 | DOID:2773 |
| Angioedema | indication | 41291007 | DOID:1558 |
| Humoral hypercalcemia of malignancy | indication | 47709007 | |
| Articular gout | indication | 48440001 | DOID:13189 |
| Edema of larynx | indication | 51599000 | |
| Nephrotic syndrome | indication | 52254009 | DOID:1184 |
| Systemic lupus erythematosus | indication | 55464009 | DOID:9074 |
| Allergic rhinitis | indication | 61582004 | |
| Löffler's syndrome | indication | 64936001 | DOID:9503 |
| Pemphigus | indication | 65172003 | DOID:9182 |
| Tenosynovitis | indication | 67801009 | DOID:970 |
| Rheumatoid arthritis | indication | 69896004 | DOID:7148 |
| Transfusion reaction due to serum protein reaction | indication | 72284000 | |
| Acquired thrombocytopenia | indication | 74576004 | DOID:11126 |
| Thyroiditis | indication | 82119001 | DOID:7166 |
| Bursitis | indication | 84017003 | DOID:2965 |
| Autoimmune disease | indication | 85828009 | |
| Infection by larvae of Trichinella spiralis | indication | 88264003 | |
| Congenital hypoplastic anemia | indication | 88854002 | DOID:1339 |
| Acute lymphoid leukemia | indication | 91857003 | DOID:9952 |
| Dermatitis herpetiformis | indication | 111196000 | DOID:8505 |
| Hodgkin's disease | indication | 118599009 | |
| Non-Hodgkin's lymphoma | indication | 118601006 | |
| Mycosis fungoides | indication | 118618005 | |
| Aspiration pneumonitis | indication | 155597006 | |
| Asthma | indication | 195967001 | DOID:2841 |
| Transplanted organ rejection | indication | 213148006 | |
| Adrenogenital disorder | indication | 267395000 | DOID:0050811 |
| Eruption of skin | indication | 271807003 | DOID:0050486 |
| Disorder of eye | indication | 371405004 | DOID:5614 |
| Primary adrenocortical insufficiency | indication | 373662000 | |
| Adrenal cortical hypofunction | indication | 386584007 | DOID:10493 |
| Erythroderma | indication | 399992009 | |
| Autoimmune hemolytic anemia | indication | 413603009 | DOID:718 |
| Synovitis | indication | 416209007 | DOID:2703 |
| Post traumatic osteoarthritis | indication | 699262001 | |
| Erythroblastic Anemia | indication | ||
| Diagnostic Test for Cushing's Syndrome | indication | ||
| Transfusion Reaction Urticaria | indication | ||
| Systemic Dermatomyositis | indication | ||
| Synovitis due to Osteoarthritis | indication | ||
| Respiratory distress syndrome in the newborn | off-label use | 46775006 | |
| Neonatal Bronchopulmonary Dysplasia | off-label use | ||
| Mycosis | contraindication | 3218000 | DOID:1564 |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Inactive tuberculosis | contraindication | 11999007 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Measles | contraindication | 14189004 | DOID:8622 |
| Esophagitis | contraindication | 16761005 | DOID:11963 |
| Mood swings | contraindication | 18963009 | |
| Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Abscess of intestine | contraindication | 24557004 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Infectious disease | contraindication | 40733004 | |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Hypokalemia | contraindication | 43339004 | |
| Chronic heart failure | contraindication | 48447003 | |
| Duodenal ulcer disease | contraindication | 51868009 | DOID:1724 |
| Osteoporosis | contraindication | 64859006 | DOID:11476 |
| Psychotic disorder | contraindication | 69322001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hypopituitarism | contraindication | 74728003 | DOID:9406 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Bilateral cataracts | contraindication | 95722004 | |
| Eye infection | contraindication | 128351009 | |
| Disorder of muscle | contraindication | 129565002 | DOID:423 |
| Anastomosis of intestine | contraindication | 235407009 | |
| Diverticulitis of gastrointestinal tract | contraindication | 271366000 | |
| Varicella-zoster virus infection | contraindication | 309465005 | |
| Viral eye infection | contraindication | 312132001 | |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Exposure to varicella | contraindication | 444453009 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.23 | acidic |
| pKa2 | 12.94 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
| Glucocorticoid receptor | Transcription factor | Kd | 6.72 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00978 | KEGG_DRUG |
| 4017945 | VUID |
| N0000146295 | NUI |
| 83784-20-7 | SECONDARY_CAS_RN |
| 4017945 | VANDF |
| C0056387 | UMLSCUI |
| CHEBI:5782 | CHEBI |
| CHEMBL977 | ChEMBL_ID |
| CHEMBL3989663 | ChEMBL_ID |
| CHEMBL1200495 | ChEMBL_ID |
| DB14545 | DRUGBANK_ID |
| C007133 | MESH_SUPPLEMENTAL_RECORD_UI |
| LIU00Z1Z84 | UNII |
| 16623 | PUBCHEM_CID |
| 21651 | RXNORM |
| 20708 | MMSL |
| 41706 | MMSL |
| 4843 | MMSL |
| 73114 | MMSL |
| 002152 | NDDF |
| 005251 | NDDF |
| 109066000 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Solu-Cortef | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0005 | INJECTION, POWDER, FOR SOLUTION | 1000 mg | INTRAMUSCULAR | NDA | 22 sections |
| Solu-Cortef | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0011 | INJECTION, POWDER, FOR SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |
| Solu-Cortef | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0013 | INJECTION, POWDER, FOR SOLUTION | 250 mg | INTRAMUSCULAR | NDA | 22 sections |
| Solu-Cortef | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0016 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAMUSCULAR | NDA | 22 sections |
| Solu-Cortef | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0825 | INJECTION, POWDER, FOR SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |
| SOLU-CORTEF | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1261 | INJECTION, POWDER, FOR SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 13 sections |
| SOLU-CORTEF | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1262 | INJECTION, POWDER, FOR SOLUTION | 250 mg | INTRAMUSCULAR | NDA | 13 sections |
| Solu-Cortef | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-3942 | INJECTION, POWDER, FOR SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 22 sections |